You have been selected to receive a free test alert - on us!
Dyslipidemia management requires a multifaceted approach that includes both lifestyle modifications and pharmacotherapy. The primary goal of treatment is to reduce LDL-C levels to lower cardiovascular (CV) risk. Additionally, some patients may require other therapies to address residual CV risk associated with elevated triglycerides or elevated lipoprotein(a) [Lp(a)].
The 2018 AHA/ACC/Multisociety cholesterol guideline emphasized the importance of lowering LDL-C as the primary treatment target. This guideline focuses on populations where statin therapy has been proven to lower both LDL-C and CV event risk, known as the four statin benefit groups. In 2022, the ACC published an Expert Consensus Decision Pathway for nonstatin therapy, recommending specific LDL-C thresholds for all four statin benefit groups, rather than just two as per the 2018 guideline. While statin therapy is effective in reducing CV risk and LDL-C levels, some patients may require additional nonstatin therapies to achieve optimal LDL-C reduction. Several nonstatin therapies, including ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, and inclisiran, are available and effective in further lowering LDL-C. This program will review these LDL-C lowering therapies and their optimal use to improve patient outcomes.
Even when LDL-C is reduced to recommended levels, patients with elevated triglycerides or Lp(a) remain at increased risk for CV events. Clinicians should be aware of the evidence linking elevated triglycerides and Lp(a) with CV events, as well as the latest innovations and outcomes data related to current and emerging drug therapies for these conditions. This session will review outcomes data on the use of omega-3 fatty acids in patients with elevated triglycerides. Additionally, it will cover two medications in phase III trials, pelacarsen and olpasiran, which lower Lp(a) in conjunction with statin therapy.
Joseph Saseen, PharmD, BCPS, BCACP, CLS, FASHP, FCCP, FAPhA, MNLA is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine at the University Anschutz Medical Campus. He has responsibilities for enhancing the school’s clinical enterprise, further developing sustainable clinical service models, advocating for advancing the practice of pharmacy in the state of Colorado, and manages strategic international relationships.
Dr. Saseen is a clinical pharmacist who focuses on cardiovascular risk reduction and population health. His scholarly work includes over two hundred peer-reviewed publications and book chapters. He is a past president of the National Lipid Association (NLA). Dr. Saseen is a fellow of the American College of Clinical Pharmacy, American Society of Health-system Pharmacists, American Pharmacists Association, and the American Heart Association. He is a Master of the NLA and is certified as a Clinical Lipid Specialist. He was an author of the 2018 AHA/ACC/Multisociety cholesterol management guideline, the 2022 NLA Statin Intolerance Scientific Statement, and the 2024 NLA/American Geriatrics Society Managing Hypercholesterolemia in Adults Aged 75 Years and Older Without a History of ASCVD Expert Consensus Statement.
Speaker Disclosures:
Register for this intensive training course without risk. If you're not completely satisfied, give us a call at 800-844-8260. We're that confident you'll find this learning experience to be all that's promised and more than you expected.
Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world's best instructors, and complete your CE requirements anywhere, anytime, at your own pace.
Access never expires for this product.
Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.
